Neurolief Secures Additional $6 Million Investment Following FDA Approval of Proliv™Rx, Expanding Access to Brain Neuromodulation Therapy for Patients with Inadequate Response to Antidepressants - biospace.com
Submitted by Anonymous (not verified) on Mon, 03/30/2026 - 17:03
